The oncolytic virus treatment extended survival for patients with recurrent glioblastoma, especially among patients with pre-existing viral antibodies.
“That’s hard to do with GBM, so our findings are exciting and give us hope for our next steps,” Chiocca added. Notably, GBM patients who had pre-existing antibodies to the HSV1 virus had a median overall survival of 14.2 months. Moving forward, the researchers plan to complete prospective studies to further investigate the effectiveness of the oncolytic virus in patients who do and do not have antibodies to HSV1.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: EatThisNotThat - 🏆 294. / 63 Read more »